4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-100751
CEO and President sold 1,982 shares at an average $0.69 ($1,367)
- CEO and President acquired 6,109 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Mehta Vimal · CEO and President
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-09-14 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,609 | 50,148 | D | ||
| 2024-09-15 | Exercise or conversion : show line 2 in the form 10b5-1 | +3,500 | 53,648 | D | ||
| 2024-09-16 | Sale : show line 3 in the form 10b5-1 | −832 | $0.69 | $573 | 52,816 | D |
| 2024-09-16 | Sale : show line 4 in the form 10b5-1 | −1,150 | $0.69 | $794 | 51,666 | D |
| Open-market sales · 1,982 sh · avg $0.69 · $1,367 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-09-14 | Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units | −2,609 | 15,657 | D |
| 2024-09-15 | Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units | −3,500 | 35,000 | D |
Loading xslF345X05/tm2424255-6_4seq1.xml…